Adrenal insufficiency in growth hormone-treated patients: A reassessment

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


There is strong evidence that growth hormone (GH)-treated patients are at risk of morbidity and mortality from adrenal insufficiency. Mortality due to sudden adrenal crisis is substantially greater than that from Creutzfeldt-Jakob disease (CJD). The risk of death from adrenal insufficiency in children treated with GH persists into adulthood, even when adult GH deficiency is not apparent. Deaths related to adrenal insufficiency should be preventable. There is also evidence that very few GH-treated patients are being routinely tested for adrenal insufficiency. The importance of careful evaluation and long-term followup of adrenal function in GH-treated patients, with provision of adequate and aggressive replacement therapy when needed, is emphasized.

Original languageEnglish
Pages (from-to)328-332
Number of pages5
JournalPediatric Endocrinology Reviews
Issue numberSUPPL. 2
StatePublished - Apr 2006


  • Addison's disease
  • Adrenal insufficiency
  • Mortality risks, growth hormone recipients, growth hormone deficiency


Dive into the research topics of 'Adrenal insufficiency in growth hormone-treated patients: A reassessment'. Together they form a unique fingerprint.

Cite this